ERBB2 and neoplasm: Particularly noteworthy is human epidermal growth factor receptor 2 (HER2), an EGFR family member whose overexpression correlates with highly aggressive tumour phenotypes and poor clinical outcomes, making it an especially compelling target for precision oncology approaches [64].